Drug Trial Radar · NCT04681131
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Mar 17, 2021
Primary completion
Jul 9, 2025
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- BioAtla, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Conditions
- Non-Small-Cell Lung Cancer
Interventions
CAB-AXL-ADCBiological
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitorBiological
PD-1 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) per RECIST v1.1Time frame: Up to 24 months
- Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5Time frame: Up to 24 months
Locations
60 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope - Duarte
Duarte, California
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
Irvine, California
California Research Institute
Los Angeles, California
USC Norris
Los Angeles, California
Cedars-Sinai
Los Angeles, California
University of California, San Diego (UCSD) - Moores Cancer Center
San Diego, California
American Institute of Research
Whittier, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Florida Cancer Specialists & Research Institute
Fleming Island, Florida
Florida Cancer Specialists & Research Institute
Fort Myers, Florida
Florida Cancer Specialist
St. Petersburg, Florida
Moffitt Cancer Center
Tampa, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Augusta University - Georgia Cancer Center
Augusta, Georgia
Baptist Health Systems
Lexington, Kentucky
University of Kentucky
Lexington, Kentucky
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville, Kentucky
Hematology/Oncology Clinic
Baton Rouge, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Detroit, Michigan
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
OptumCare Cancer Care
Las Vegas, Nevada
Roswell Park
Buffalo, New York
NYU Langone Health
New York, New York
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina
Gabrail Cancer Research Center
Canton, Ohio
The Lindner Research Center at the Christ Hospital
Cincinnati, Ohio
UPMC Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina- Hollings Cancer Center
Charleston, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson
Houston, Texas
Henry Dunant Hospital Center
Athens, Greece
Metropolitan Hospital Perseus Healthcare Group SA
Piraeus, Greece
Bioclinic Thessaloniki
Thessaloniki, Greece
European Interbalkan Medical Center
Thessaloniki, Greece
ICON Cancer Centre
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Hong Kong United Oncology Centre
Kowloon, Hong Kong
Hospital San Giuseppe Moscati
Avellino, Italy
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.